Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

(Low)

(Positive)

Key Terms

plasma fractionation medical

Plasma fractionation is the industrial process of separating donated blood plasma into its useful protein components—such as immunoglobulins, albumin and clotting factors—using physical and chemical methods. Think of it like separating milk into cream, butter and cheese: each component becomes a distinct medical product. It matters to investors because the process is capital- and regulation-intensive, creates high-value biologic medicines with steady demand, and is sensitive to supply, capacity and quality controls that affect revenue and risk.

plasma-derived medicinal products medical

Medicines made from the liquid portion of human blood (plasma) after donors are pooled and processed to isolate proteins such as immunoglobulins, clotting factors and albumin. They are used to treat immune deficiencies, bleeding disorders and other medical conditions. Investors care because these therapies rely on complex, regulated collection and manufacturing systems, create steady demand and pricing sensitivity, and can be affected by supply shortages or regulatory changes like a staple product that needs consistent raw material and oversight.

biopharmaceutical manufacturing technical

The controlled process of producing medicines and vaccines derived from living cells or biological molecules, using specialized facilities, equipment and strict quality controls to ensure safety and consistency. It matters to investors because these operations are capital‑intensive and technically complex: production capacity, regulatory compliance, and the ability to scale reliably directly affect a drug’s supply, cost structure and revenue prospects, much like a bakery’s ovens and recipes determine how many loaves it can sell without spoiling.

plasma donation centers medical

Facilities where trained staff collect and process blood plasma from volunteer donors for use in life-saving therapies and medical products. They matter to investors because they are the operational hubs that generate revenue from plasma sales, are subject to health and safety regulations, and can be affected by supply limits, donor incentives, and reimbursement policies—like a factory in a supply chain that must meet strict quality rules to keep products flowing to the market.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/12/2026 - 07:00 PM

Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda to Collect and Fractionate Plasma as Part of Multi-Phased Initiative
Takeda Will Initially Invest up to 30 Million U.S. Dollars to Begin the Establishment of an Ecosystem for Plasma-Derived Medicinal Products, including a pilot of a National Plasma Donation Network
Collaboration Builds on Decades-Long Relationship Between Takeda and Indonesia Focused on Elevating Healthcare Standards for Patients

OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Industry/BKPM and the Coordinating Ministry for Economic Affairs) today announced a groundbreaking collaboration aimed at strengthening Indonesia’s plasma ecosystem and supporting more equitable access to lifesaving plasma-derived medicinal products (PDMPs) in Indonesia and around the world. Marked by a fractionation license granted to Takeda by the Ministry of Health (MoH), the collaboration is a major milestone in advancing Indonesia’s health resilience and biopharmaceutical manufacturing capabilities.

“This initiative reflects Indonesia’s commitment to building strategic healthcare capabilities and ensuring sustainable access to essential and innovative therapies for Indonesian patients,” said Minister Budi Gunadi Sadikin, Ministry of Health, Republic of Indonesia. “By working closely with trusted global partners like Takeda, we can accelerate the development of a more resilient, future-ready healthcare system.”

The vision for this multi-year initiative, the first of its kind in the Association of Southeast Asian Nations (ASEAN) region, is focused on the sustainable collection of high-quality plasma and manufacturing of PDMPs at scale. Building on Takeda’s long-standing presence in Indonesia, the collaboration has the potential to position the country as a regional hub for plasma science, advanced plasma collection and biopharmaceutical manufacturing and innovation.

“This initiative demonstrates Takeda’s commitment to expanding access to PDMPs, advancing healthcare resilience and supporting sustainable health systems,” said Ramy Riad, President, Plasma-Derived Therapies at Takeda. “From the introduction of our first PDMPs in Indonesia earlier this year to our investment in local plasma infrastructure, we are proud to extend our collaboration with Indonesia and leverage our global expertise in plasma science to support Indonesia’s long-term healthcare objectives. Together, we aim to improve standards of care, create highly skilled jobs and bolster long-term supply of lifesaving, life-sustaining therapies for patients in Indonesia and around the world.”

As part of the initial phase of the project, Takeda will invest up to 30 million U.S. dollars in a two-year pilot program to establish plasma donation centers in Indonesia, enabling Takeda and the MoH to evaluate feasibility and refine operational models ahead of a potential scale-up into a national network. These centers will leverage Takeda’s global plasma donation expertise and adhere to stringent international quality and regulatory standards. The initiative is expected to create new employment opportunities, including highly skilled positions for healthcare professionals and laboratory technicians, while supporting workforce training and the transfer of international standard practices.

In parallel, Takeda will assess the feasibility and regulatory requirements for building a state-of-the-art plasma-derived therapy manufacturing facility in Indonesia that could serve both Indonesia and other parts of the world – positioning the country as an important contributor to the global supply chain for advanced healthcare products and technologies.

"This investment represents the type of strategic, long-term investment that Indonesia seeks to attract. Beyond the capital commitment, it brings opportunities for technology transfer, talent development and job creation. The collaboration not only elevates and strengthens Indonesia’s healthcare ecosystem but also supports our ambition to establish Indonesia as a regional hub for advanced life sciences and biopharmaceutical manufacturing,” said Minister of Investment and Downstream Industry / Chairman of BKPM, Rosan P. Roeslani.

Global demand for PDMPs continues to grow, yet many countries across the ASEAN region, including Indonesia, face challenges in ensuring sustainable access to these therapies. Underdiagnosis and limited awareness of conditions that can be addressed by PDMPs also remain key barriers to care. This collaboration is intended to support the reliable supply of plasma and PDMPs for patients domestically, while contributing to a more resilient global plasma ecosystem. By sharing best practices in plasma collection and processing, building local capabilities, raising awareness and investing in workforce training, this initiative aims to further enhance patient care in Indonesia and across the region.

The first plasma donation center is expected to open in 2027, and all locations will be part of Takeda’s BioLife plasma center network. While the feasibility of a manufacturing facility is assessed, plasma collected in Indonesia will be fractionated within Takeda’s existing global manufacturing network, with a commitment to prioritizing Indonesia’s domestic needs for PDMPs, in line with applicable laws and regulations.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

In Indonesia, Takeda has contributed to the country's healthcare improvement for more than 50 years, since 1971, covering a broad set of expertise, including oncology, gastroenterology, rare diseases, vaccines, and consumer healthcare. We are dedicated to expanding access to our innovative treatments for more patients in Indonesia, fostering enduring partnerships with diverse stakeholders to enhance patient outcomes and sustain the healthcare system in the long term. For more information, visit https://www.takeda.com/id-id/.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global healthcare reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products and business collaborations and ventures; difficulties or delays including with respect to the construction, validation, qualification, scale-up or operation of plasma collection centers or manufacturing facilities; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.